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CC BY-NC-ND license (http://creativeBackground: Aerosolized colistin methanesulfonate (CMS) has been used for the treatment of
extensively drug-resistant Acinetobacter baumannii (XDRAB) pneumonia and eradication of
XDRAB colonization in the respiratory tract. The aims of this study were to compare the effi-
cacy, adverse effects, clinical outcomes, and microbiological eradication of the cases of XDRAB
pneumonia or colonization.
Methods: We retrospectively reviewed the medical records of patients who received aerosol-
ized CMS for the treatment of pneumonia and airway colonization due to XDRAB.
Results: Clinical data from 118 patients were studied. The mean age of 57 patients in the
pneumonia group was 79.4 years, and that of 61 patients in the colonization group was 80.0
years. Patients with XDRAB pneumonia were more likely to be ventilator-dependent than colo-
nized patients (46.5% vs. 21.3%; p Z 0.005), receive steroid therapy (49.1% vs. 31.1%;
p Z 0.046), and be admitted to an intensive care unit (ICU) at the time of aerosolized CMS
treatment (56.1% vs. 32.8%; pZ 0.011). The in-hospital mortality rate was higher in the pneu-
monia group than the colonization group (50.9% vs. 33.3%; pZ 0.05). Microbiological eradica-
tion of XDRAB in airway samples was achieved in 75% (89 of 118) patients. In pneumoniaInfectious Disease, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University,
ad, Taipei 116, Taiwan.
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524 T.-C. Hsieh et al.patients, XDRAB eradication was associated with resolution or improvement of presenting
symptoms and signs of infection by the end of treatment relative to the noneradicated group
(57.8% vs. 25%; pZ 0.044), but had no influence on 30-day mortality. In colonized patients, no
difference in clinical outcomes was noted between the eradicated and noneradicated groups.
Conclusion: Aerosolized CMS therapy has acceptable efficacy for XDRAB pneumonia, but no
proven efficacy for XDRAB airway colonization.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Extensively drug-resistant Acinetobacter baumannii
(XDRAB) is one of the most notorious and challenging
pathogens for health care institutions worldwide. The or-
ganism’s ability to survive and persist for long periods under
various environmental conditions poses great challenges for
hospital infection control.1,2 Patients who are colonized or
infected with XDRAB can become a reservoir of infection.
Indeed, it has been shown that A. baumannii can colonize
multiple body sites in hospitalized patients,3 especially in
those who are ventilator dependent.
The commercially available antibiotic most active
against XDRAB in vitro is polymyxin: polymyxin B or poly-
myxin E (colistin).4,5 Colistin methanesulfonate (CMS) is a
prodrug that is hydrolyzed after intravenous administration
to produce several derivatives, predominately the active
drug colistin.6 However, renal toxicity related to intrave-
nous CMS use remains a major concern in critically ill pa-
tients.7 Another problem is that the colistin concentration
in the lung tissue is relatively low when administered
intravenously.8 Therefore, aerosolized CMS has become a
reasonable choice for minimizing systemic exposure and
optimizing the benefiterisk ratio of therapy. Aerosolized
CMS has been used as a monotherapy9,10 or as an adjuvant
to intravenous antibiotics in XDRAB pneumonia.5,11 Some
hospitals in Taiwan have also employed aerosolized CMS for
eradication of XDRAB as part of their infection control
measures.12
Despite the increasing use of aerosolized CMS for XDRAB
pneumonia, its clinical benefit has not been well studied.
Bacterial colonization of the airway is crucial for develop-
ment of nosocomial pneumonia.13 Theoretically, eradica-
tion of XDRAB respiratory tract colonization may prevent
development of true infection, but the clinical benefits of
such eradication in colonized patients remain unproven.
In this study, we evaluated the efficacy and adverse
effect of aerosolized CMS and the risk factors of 30-day
mortality in cases of XDRAB pneumonia and airway
colonization.
Methods
This retrospective study was conducted at Wan Fang Med-
ical Center, a teaching hospital of Taipei Medical University,
Taipei, Taiwan. We reviewed the medical charts of the
patients who were treated with aerosolized CMS
(Colimycin; TTY Biopharm, Taipei, Taiwan) for XDRABpneumonia or airway colonization from January 1, 2012 to
August 31, 2013.
Data collection and definitions
Clinical data or laboratory parameters were collected using
a standard form, in which definitions were predefined. The
collected data included demographic characteristics, un-
derlying conditions, Acute Physiology and Chronic Health
Evaluation (APACHE) II score within 48 hours of the first
dose of aerosolized CMS therapy, characteristics of XDRAB
isolates, antimicrobial therapy, and clinical and microbio-
logical outcomes of each patient.
Microbiological testing
Acinetobacter calcoaceticusebaumannii complex (Acb
complex) identification and antimicrobial susceptibility
testing were performed using the Becton Dickinson Phoenix
TM Automated Microbiology System (Becton Dickinson, East
Rutherford, NJ, USA). The susceptibility to tigecycline (TG)
(pfizer, catania, Italy) was assessed by using the disk
diffusion method. Antimicrobial susceptibility breakpoints
followed those defined by the Clinical and Laboratory
Standards Institute.14 Because Acb complex cannot be
separated reliably by phenotypic methods alone, all the
species identified as Acinetobacter baumannii in this paper
were Acb complex. Colistin susceptibility was defined as a
colistin minimum inhibitory concentration (MIC) of  2 mg/
L, and colistin resistance as MIC > 2 mg/L, according to the
breakpoints published by the European Committee on
Antimicrobial Susceptibility Testing for Acinetobacter spe-
cies.15 The disk diffusion breakpoints for TG were  19 mm
and  14 mm for susceptible and resistant, respectively, as
the criteria recommended by the United States Food and
Drug Administration for Enterobacteriaceae.16 XDRAB was
defined as the Acb complex isolates susceptible to only one
or two antibiotic categories as described previously.17
Inclusion and exclusion criteria
Only adult patients (aged at least 20 years) from whom only
XDRAB was obtained from at least one set of airway samples
and who received > 72 hours of aerosolized CMS therapy,
with available subsequent culture results of airway samples,
which were collected every 3e5 days until 14 days after the
end of inhaled CMS therapy, were included in this study.
Aerosolized colistin methanesulfonate therapy 525The day that CMS therapy was initiated for the XDRAB
isolate in airway samples was defined as the index day, and
the XDRAB isolate as the index isolate. The dosage of
inhaled CMS used was 2 million international units (IU)
twice per day, administered in nebulized form. Patients
were categorized as either the pneumonia or colonization
group, according to published criteria.18
Definitions of outcomes
The 30-day mortality was defined as the crude mortality
within 30 days after the index day, and in-hospital mortality
as the death during the same hospitalization.
Microbiological eradication was defined as no XDRAB
found in subsequent sputum cultures within 14 days after
the end of aerosolized CMS therapy. Microbiological failure
was the continued isolation of XDRAB from sputum culture
under aerosolized CMS or the recovery of XDRAB within 14
days after CMS therapy.
We also recorded the adverse effects related to CMS
inhalation. Bronchospasm was defined as new-onset bron-
chospasm during CMS inhalation, or the need for increasing
the dose or frequency of already used bronchodilators.
Renal function was assessed by the Risk, Injury, Failure,
Loss of kidney function, and End-stage kidney disease
(RIFLE) criteria.19 Nephrotoxicity in this study was referred
to the risk group, according to the RIFLE criteria. The pa-
tients with renal replacement therapy were excluded from
the evaluation of nephrotoxic effects.
In a subgroup analysis of patients with XDRAB pneu-
monia, we classified clinical outcomes as favorable (reso-
lution or improvement of presenting symptoms and signs of
infection by the end of treatment), or unfavorable (no
improvement, persistence or worsening of presenting
symptoms, and/or signs of XDRAB infection during CMS
administration).
Statistical analysis
We compared categorical and continuous variables with c2
or Fisher’s exact tests and the independent t test, respec-
tively. A p value  0.05 was considered to be statistically
significant and two-tailed tests were adopted for all prob-
abilities. The significant variables in the univariate analysis
were included in a multivariate logistic regression analysis
to calculate odds ratios (ORs). All statistical analysis was
performed with SPSS version 21 (IBM, Armonk, NY, USA).
Results
During the study period, a total of 237 patients received
aerosolized CMS therapy. However, the Acb complex iso-
lates from 37 patients did not fulfill the criteria of XDR, 17
received aerosolized CMS for other pathogens, and six
received aerosolized CMS for < 72 hours. Subsequent
sputum cultures were not available in 42 patients, and 17
patients had concurrent bacterial or fungal infections (4
fungemia, 4 complicated intra-abdominal infections, and 9
pneumonia caused by other organisms). The above 119
patients were excluded. Finally, 118 patients were
included.Of 118 patients, 57 (48%) patients had XDRAB pneumonia
and 61 (52%) were colonized by XDRAB. The demographic
data, underlying medical conditions, microbiological char-
acteristic of XDRAB isolates, antimicrobials therapy, and
clinical outcomes of these two groups are summarized in
Table 1. Patients with XDRAB pneumonia were more likely
to be ventilator dependent than colonized patients (46.5%
vs. 21.3%; p Z 0.005), receive steroid therapy (49.1% vs.
31.1%; p Z 0.046), and be admitted to an intensive care
unit (ICU) at the time of aerosolized CMS treatment (56.1%
vs. 32.8%; p Z 0.011). Only 4 (6.5%) patients with XDRAB
had concurrent XDRAB bacteremia. The colonization group
was more likely to receive aerosolized CMS alone than the
pneumonia group (50.8% vs. 15%; p Z 0.03). The mean
duration of CMS inhalation was longer in the pneumonia
group than the colonization group (13.49  6.5 days vs.
11  4.8 days; pZ 0.02). The in-hospital mortality rate was
higher in the pneumonia group than in the colonized group
(50.9% vs. 33.3%; p Z 0.05).
Microbiological eradication of XDRAB was achieved in
75% (89 of 118 patients), i.e., 72.1% (44 of 61 patients) with
colonization and 78.9% (45 of 57) with pneumonia. The
mean duration of CMS use prior to XDRAB eradication was
5.3  2 days. Follow-up XDRAB isolates from 12 patients
with pneumonia and 16 with colonization were analyzed. A
two-fold increase of colistin MIC was noted in five (17.8%) of
28 patients, including four with colonization and one with
pneumonia. Only one isolate from the colonization group
developed colistin resistance (MIC > 2 mg/L).
After excluding three patients with regular hemodialy-
sis, 115 patients were evaluated for renal side effects.
Acute kidney injury was noted in 26 (22.6%) of patients and
no renal replacement was needed. There were two epi-
sodes of bronchospasm related to inhaled CMS in two pa-
tients with underlying chronic obstructive pulmonary
disease (COPD). Further events were prevented by pro-
phylactic administration of bronchodilator prior to aero-
solized CMS therapy. No neurotoxicity related to
aerosolized CMS and no treatment interruptions due to drug
toxicity were noted in our cases.
In the subgroup analysis of XDRB pneumonia, those with
airway eradication of XDRAB had more favorable clinical
outcomes than those with eradication (57.8% vs. 25%;
p Z 0.044; Table 2). Patients with XDRAB eradication ten-
ded to have a lower 30-day mortality rate than those
without eradication (28.9% vs. 58.3%; p Z 0.06). In the
colonization group, there was no difference in 30-day
mortality rate between those with and without microbio-
logical eradication (25% vs. 35.3%; pZ 0.42). However, the
development of increased colistin MIC was noted in 23.5% of
17 XDRAB isolates obtained from the colonization group
without microbiological eradication.
Clinical factors associated with 30-day mortality are
summarized in Table 3. In the pneumonia group, age, sex,
and infection sources did not have a significant impact on
30-day mortality. In the multivariate logistic regression
model, the two factors significantly associated with 30-day
mortality were underlying COPD [adjusted OR (aOR)Z 7.0;
95% confidence interval (CI) Z 1.8e26.8; p Z 0.004] and
malignancy (aOR Z 8.9; 95% CI Z 1.7e45.6; p Z 0.01). In
the colonization group, 30-day mortality was significantly
related to a previous cerebral vascular accident (CVA) with
Table 1 Clinical and microbiological characteristics of patients with extensively drug-resistant Acinetobacter baumannii
(XDRAB) pneumonia or airway colonization
Variables Case number (%) or mean ( standard deviation) p
Colonization (n Z 61) Pneumonia (n Z 57)
Male 43 (70.5) 33 (57.9) 0.153
Age (y) 80.0 ( 10.9) 79.4 ( 12.1) 0.563
Body mass index 20.9 ( 4.0) 20.2 ( 3.7) 0.325
APACHE II score 17.0 ( 8.0) 18.1 ( 6.5) 0.413
APACHE II score >21 19 (31.1) 18.0 (31.6) 0.960
Underlying conditions
COPD 19 (31.1) 18 (31.6) 0.960
Congestive heart failure 37 (60.7) 34 (59.6) 0.911
Cerebral vascular disease 36 (59.0) 33 (59.9) 0.902
Malignancy 7 (11.5) 10 (17.5) 0.348
Diabetes mellitus 29 (47.5) 26 (45.6) 0.834
Chronic renal failure (GFR < 60) 15 (24.0) 14 (24.5) 0.349
End-stage renal disease 3 (4) 0 0.349
Steroid therapya 19 (31.1) 28 (49.1) 0.046
Immunosuppressive therapy 1 (1.6) 2 (3.5) 0.519
Mechanical ventilator use
Noninvasive 12 (19.7) 16 (28.1) 0.284
Invasive 13 (21.3) 26 (45.6) 0.005
Antibiotic therapy, in addition to aerosolized CMS 0.030
None 31 (50.8) 9 (15)
Tigecycline 21 (34.4) 29 (50.9)
Sulbactam 5 (8.2) 6 (10.5)
Cephalosporin 1 (1.6) 1 (1.8)
Carbapenem 1 (1.6) 7 (12.3)
Intravenous CMS 1 (1.6) 4 (7.0)
Duration of aerosolized CMS therapy (d) 11.0 ( 4.8) 13.5 ( 6.5) 0.02
Acquisition place of XDRAB isolates
Nursing home 15 (24.6) 10 (17.5) 0.349
ICU 20 (32.8) 32 (56.1) 0.011
Ward 28 (45.9) 15 (26.3) 0.027
XDRAB bacteremia 0 (0) 4 (6.5) 0.031
Tigecycline susceptibility 0.750
Susceptible 38 (62.3) 28 (49.1)
Intermediate 20 (32.8) 19 (33.3)
Resistant 3 (4.9) 10 (17.5)
Clinical and microbiological outcomes
Length of hospital stay (d) 39.8 ( 22.5) 48.9 ( 30.4) 0.070
Nephrotoxicity 14 (23) 12 (21.1) 0.804
XDRAB airway eradication 44 (72.1) 45 (78.9) 0.390
30-day mortality 17 (27.9) 19 (33.3) 0.519
In-hospital mortality 20 (33.3) 29 (50.9) 0.050
a Daily 20 mg prednisolone or its equivalent for at least 1 week in the preceding 2 weeks.
APACHE II Z Acute Physiology and Chronic Health Evaluation II; CMS Z colistin methanesulfonate; COPD Z chronic obstructive pul-
monary disease; GFR Z glomerular filtration rate; ICU Z intensive care unit.
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score > 21, and development of nephrotoxicity. However,
in the multivariate analysis, only previous CVA with
bedridden status was associated with 30-day mortality
(aOR Z 4.3; 95% CI Z 1.1e15.9; p Z 0.03).
The subgroup analysis of those patients receiving CMS
inhalation alone or in combination with intravenous
tigecycline (IVTG) is summarized in Table 4. Of note,
there were 21 (34.4%) of 61 patients with XDRAB airway
colonization receiving IVTG therapy. The colonizationstreated with CMS inhalation in combination with IVTG
were less likely to achieve microbiological eradication
than those with CMS inhalation alone (42.9% vs. 87.9%;
p Z 0.001).
In the pneumonia group, there was no difference in
airway XDRAB eradication rate, favorable clinical outcome,
or 30-day or in-hospital mortality rate, between those with
CMS inhalation alone and those with combination therapy
(Table 4). The initial XDRAB isolates in the CMS þ IVTG
group were more likely to be sensitive to TG (72.4% vs.
Table 2 Comparison of cases of extensively drug-resistant Acinetobacter baumannii (XDRAB) pneumonia and colonization
with or without microbiological eradication
Variables Pneumonia (n Z 57) Colonization (n Z 61)
Eradicated
(n Z 45)
Noneradicated
(n Z 12)
p Eradicated
(n Z 44)
Noneradicated
(n Z 17)
p
Male (%) 24 (53.3) 9 (75.0) 0.177 33 (75) 10 (58.8) 0.214
Age (y) 79.5  11.7 78.8  14.4 0.861 80.3  10.5 81.2  11.8 0.774
APACHE II score 17.6  6.0 20.3  8.2 0.310 14.64  6 18.3  8.3 0.082
Underlying conditions
Congestive heart failure 17 (37.8) 6 (50.0) 0.443 20 (45.5) 4 (23.5) 0.116
COPD 13 (28.9) 5 (41.7) 0.397 14 (31.8) 5 (29.4) 0.856
Cerebral vascular disease 27 (60.0) 6 (50.0) 0.533 25 (56.8) 11 (64.7) 0.574
Malignancy 7 (15.6) 2 (16.4) 0.445 5 (11.4) 2 (11.8) 0.965
Diabetes mellitus 21 (46.7) 5 (41.7) 0.757 21 (47.7) 8 (47.1) 0.963
Chronic renal failure (GFR < 60) 12 (26.4) 14 (24.5) 0.706 7 (15.8) 5 (29.4) 0.224
End-stage renal disease 3 (4) 0 0.473 2 (4.5) 1 (5.9) 0.856
Steroid usea 21 (46.7) 7 (58.3) 0.457 14 (31.8) 5 (26.3) 0.531
Mechanical ventilator use
Noninvasive 11 (24.4) 5 (41.7) 0.238 7 (15.9) 5 (29.4) 0.234
Invasive 21 (46.7) 5 (41.7) 0.757 9 (20.5) 4 (23.5) 0.793
Antibiotic therapy, in addition to aerosolized CMS 0.986 0.028
None 7 (15.6) 2 (16.7) 27 (61.4) 4 (23.5)
Tigecycline 23 (51.1) 6 (50.0) 9 (20.5) 12 (70.6)
Sulbactam 5 (12.1) 1 (8.3) 4 (9.1) 1 (5.9)
Cephalosporin 1 (2.2) 0 (0) 1 (2.3) 0
Carbapenem 5 (11.1) 2 (16.7) 1 (2.3) 0
Intravenous CMS 3 (6.7) 1 (8.3) 1 (2.3) 0
Acquisition place of XDRAB isolates
Nursing home 7 (15.6) 3 (25.0) 0.445 8 (18.2) 7 (41.2) 0.061
ICU 24 (53.3) 8 (66.7) 0.408 17 (38.6) 3 (17.6) 0.117
Ward 14 (31.1) 1 (8.3) 0.111 19 (43.2) 9 (52.9) 0.493
Clinical and microbiological outcomes
Favorable clinical response 26 (57.8) 3 (25.0) 0.044
30-day mortality 13 (28.9) 7 (58.3) 0.058 11 (25) 6 (35.3) 0.421
In-hospital mortality 21 (46.7) 8 (66.7) 0.218 12 (27.9) 8 (47.1) 0.156
Nephrotoxicity 10 (22.2) 2 (16.7) 0.675 10 (22.7) 4 (23.5) 0.947
Length of hospital stay (d) 46.2  28 58.8  35 0.203 50.4  29 35.8  18 0.068
a Daily 20 mg prednisolone or its equivalent for at least 1 week in the preceding 2 weeks.
Results are expressed as the n (%) or mean  standard deviation.
APACHE II Z Acute Physiology and Chronic Health Evaluation II; CMS Z colistin methanesulfonate; COPD Z chronic obstructive pul-
monary disease; GFR Z glomerular filtration rate; ICU Z intensive care unit.
Aerosolized colistin methanesulfonate therapy 52722.2%; pZ 0.02). Of 28 patients with pneumonia caused by
XDRAB isolates susceptible to both colistin and tigecycline,
the 30-day mortality rate of those treated by CMS inhala-
tion alone or combination therapy was similar (2/7, 28.6%
vs. 6/22, 28.6%, p > 0.99).
Discussion
In this retrospective study, we showed that aerosolized CMS
therapy could be used for eradication of XDRAB from the
respiratory tract with a satisfactory response rate. Airway
eradication of XDRAB among the patients with pneumonia
was associated with more favorable clinical outcomes than
those without XDRAB eradication.
In our study, among the pneumonia group, airway
cleaning of XDRAB was associated with more favorable
clinical outcomes, but not with a lower in-hospitalmortality rate or hospital stay. A poor correlation between
microbiological clearance and clinical outcome in patients
with XDRAB infection has been reported previously.18,20
However, in the pneumonia group, a higher 30-day mor-
tality rate was associated with underlying COPD and ma-
lignancy. These findings were compatible with previous
studies,11,21 in which underlying comorbidities were asso-
ciated with unfavorable outcomes in XDRAB infection,
irrespective of antimicrobial regimens. Thus, our study in-
dicates that the underlying comorbidity, but not microbio-
logical eradication of XDRAB in the airway, is one of the
major determinants of 30-day mortality.
In the colonization group, no improved survival or clin-
ical benefit was noted with eradication of XDRAB from the
respiratory tract. In those patients, chronic bedridden
status was the only factor associated with 30-day mortality
by the multivariate analysis. In a caseecontrol study
Table 3 Univariate and multivariate analyses of clinical variables associated with 30-day mortality in cases of extensively
drug-resistant Acinetobacter baumannii (XDRAB) pneumonia and colonization
Variables Univariate analysis p Multivariate analysis p
OR (95% CI) aOR (95% CI)
XDRAB pneumonia
COPD 5.2 (1.6e7.5) 0.007 7.0 (1.8e26.8) 0.004
Malignancy 6.1 (1.4e27.2) 0.018 8.9 (1.7e45.6) 0.010
XDRAB colonization
Old stroke 3.9 (1.2e12.8) 0.023 4.3 (1.2e15.9) 0.030
Chronic renal failure 2.1 (1.2e3.6) 0.011
APACHE II score > 21 3.8 (1.2e12.5) 0.026
Nephrotoxicity 5.6 (1.6e20.3) 0.008
aORZ adjusted odds ratio; APACHE IIZ Acute Physiology and Chronic Health Evaluation II; CIZ confidence interval; COPDZ chronic
obstructive pulmonary disease; OR Z odds ratio.
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mixed population (both XDRAB-infected and -colonized
patients) for eradication of XDRMB from the respiratory
tract, recognized benefits were the shortening of contact
isolation duration and reduction of cost for isolation mea-
sures.12 As XDRAB can colonize multiple body sites3 and
survive for a long time in the environment,1,2 eradication of
XDRAB from the respiratory tract may not be an effective
hospital infection control measure. Further studies are
needed to evaluate the impact of such a practice on hos-
pital infection control.
The incidence of renal injury in our study was 21e23%,
as assessed by the RIFLE criteria. In a recent study that
used the RIFLE criteria to evaluate intravenous CMS-related
nephrotoxicity in young patients (average age 27 years)Table 4 Comparison of cases of extensively drug-resistant Ac
treated by colistin methanesulfonate (CMS) inhalation alone or in
Variables Pneumonia (n Z 3
CMS inhalation
(n Z 9)
CMS inhalation
(n Z 29)
Male (%) 3 (33.3) 19 (65.5)
Age (y) 82.2  16.1 79.2  9.9
APACHE II score 16.4  4.6 17.8  7.3
Underlying conditions
COPD 3 (33.3) 8 (27.6)
Cerebral vascular disease 6 (66.7) 18 (62.1)
Malignancy 2 (22.2) 6 (20.7)
Onset at ICU 3 (33.3) 17 (58.6)
Mechanical ventilator
Noninvasive 3 (33.3) 9 (31.0)
Invasive 2 (22.2) 14 (48.3)
Tigecycline susceptibility 2 (22.2) 21 (72.4)
Clinical and microbiological outcomes
XDRAB eradication 7 (77.9) 23 (79.3)
30-day mortality 3 (33.3) 10 (34.5)
In-hospital mortality 5 (55.6) 15 (51.7)
Duration of hospitalization (d) 49.0  31 48.9  25
Favorable clinical outcome 5 (55.6) 15 (51.7)
Results are expressed as n (%) or mean  standard deviation.
APACHE II Z Acute Physiology and Chronic Health Evaluation II; COPD
unit.with previously normal renal function, 45% of patients had
some degree of renal dysfunction, and 21% of patients
stopped therapy secondary to nephrotoxicity.7 Nephrotox-
icity related to intravenous CMS appears to be dose-
dependent.22 The serum level of CMS given by the inhala-
tion route is much lower compared to that of the intrave-
nous route.23,24 Thus, it was likely but not proven yet that
aerosolized CMS therapy may be less nephrotoxic. The
incidence of nephrotoxicity in our study was higher than
expected. A possible reason is that our study included
elderly patients (mean age of 80 years) and those with
chronic renal insufficiency at baseline, accounting for 25%
of all patients. However, aerosolized CMS can reach the
systemic circulation,23,24 albeit in low doses. Whether low
serum CMS levels can result in renal toxicity, especially ininetobacter baumannii (XDRAB) pneumonia and colonization
combination with intravenous tigecycline (IVTG)
8) Colonization (n Z 52)
þ IVTG p CMS inhalation
(n Z 31)
CMS inhalation þ IVTG
(n Z 21)
p
0.088 24 (77.4) 12 (57.1) 0.120
0.602 81.1  12 81.6  6 0.862
0.522 14.8  6.1 18.7  8 0.066
0.740 13 (41.9) 4 (19) 0.084
0.803 21 (67.7) 10 (47.6) 0.147
0.922 3 (9.7) 4 (19) 0.331
0.184 13 (41.9) 4 (19) 0.084
0.897 6 (19.4) 5 (23.8) 0.700
0.167 6 (19.4) 5 (23.8) 0.700
0.018 16 (51.6) 16 (76.2) 0.192
0.922 27 (87.9) 12 (42.9) 0.001
0.949 8 (25.8) 7 (33.3) 0.557
0.841 9 (29) 9 (45) 0.244
0.922 37  18.9 45.4  26 0.191
0.932
Z chronic obstructive pulmonary disease; ICU Z intensive care
Aerosolized colistin methanesulfonate therapy 529elderly patients with impaired renal function, requires
further studies.
In the pneumonia group, age, sex, infection source,
underlying conditions, APACHE II score, characteristics of
XDRAB isolates, and antimicrobial therapy had no signifi-
cant impact on eradication of XDRAB. However, in the
colonization group, IVTG in combination with aerosolized
CMS was negatively associated with XDRAB eradication.
Tigecycline-based therapy for the treatment of hospital-
acquired XDRAB infections has been reported to be asso-
ciated with more microbiological failure.18,20 The mecha-
nism and clinical significance of such findings need to be
evaluated further.
Although clinical use of tigecycline for hospital-acquired
pneumonia has not been approved by the United States
Food and Drug Administration,25 IVTG has been used in
combination with aerosolized CMS in this study and failed to
improve clinical outcomes of the patients with XDRAB
pneumonia, despite the fact that the majority of XDRAB
isolates from the former population were susceptible to
tigecycline. Some investigators have suggested that tige-
cycline at the conventional doses of 100 mg loading fol-
lowed by 50 mg every 12 hours, is likely to be inadequate
for the treatment of pneumonia.26 However, given the
trend in increasing antimicrobial resistance and spread of
XDRAB infections,27,28 salvage tigecycline therapy for the
treatment of XDRAB pneumonia will increase and more
clinical studies of the tigecycline-based combination ther-
apy will be warranted.
Our study has some limitations. First, it was a single-
center, retrospective study involving a limited case num-
ber. Second, we identified A. baumannii by a phenotypic
method; therefore, it is possible that non-baumannii
Acinetobacter species were included. Third, in our
study, subsequent respiratory cultures were collected
every 3e5 days after the index day. The duration of CMS
use prior to XDRAB eradication depends on the frequency
of bacterial cultures of respiratory samples. More
frequent collection, such as daily collection of respiratory
cultures, may be necessary to determine the exact dura-
tion of aerosolized CMS before XDRAB is eradicated.
Finally, we used strict criteria to define XDRAB pneu-
monia, thus some infected patients may be included in
the colonization group because they did not fulfill the
criteria of pneumonia.
In conclusion, aerosolized CMS therapy for XDRAB
pneumonia has acceptable efficacy, but in XDRAB-colonized
patients, no survival or clinical benefit was noted in erad-
ication of XDRAB from the respiratory tract. The develop-
ment of colistin-resistant A. baumannii is a concern and
warrants cautious monitoring.Conflicts of interest
All authors declare no conflicts of interest.References
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